Plaque psoriasis is the most common clinical form of psoriasis, characterized by well-demarcated erythematous plaques with silvery scale due to chronic immune-mediated skin inflammation.
Eli Lilly reported positive phase 3b Together-PsO results for Taltz plus Zepbound in adults with plaque psoriasis and obesity or overweight. Separate meeting updates highlighted new oral plaque psoriasis therapies with biologic-like efficacy.
Johnson & Johnson said Tremfya met the primary endpoint in the Phase 3 FUZION study in active perianal fistulizing Crohn’s disease. At Week 24, both Tremfya dosing regimens showed statistically significant combined fistula remission versus placebo.
Arcutis is in focus after new Phase 3 extension data for Zoryve cream 0.05% in young children with atopic dermatitis and ahead of its Feb. 25 Q4 results. Investors are also watching recent FDA actions and pipeline updates for additional pediatric and dermatology indications.
Phase 3b TOGETHER-PsO trial shows concomitant use of ixekizumab and tirzepatide delivered superior skin clearance and weight loss versus monotherapy in adults with moderate-to-severe plaque psoriasis and obesity or overweight.
The FDA is set to make approval decisions on five drug applications in March 2026, including treatments for psoriatic arthritis, dry eye disease, hypothalamic obesity, cholestatic pruritus, and a rare genetic disorder.
Arcutis Biotherapeutics is scheduled to report fourth-quarter and full-year 2025 results on Feb. 25, after market close. Investors will focus on sales performance of Zoryve and pipeline updates.
Takeda announced positive Phase 3 results for zasocitinib in adults with moderate-to-severe plaque psoriasis, meeting all 44 endpoints. The company is also conducting a Phase 3 trial in pediatric patients.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07546214 |
A Study Comparing Tapinarof Cream 1% and Vtama® Cream 1% in the Treatment of Plaque Psoriasis. |
COMPLETED | PHASE1 |
| NCT07511647 |
A Phase 3 Clinical Study of QL2106 Injection |
NOT_YET_RECRUITING | PHASE3 |
| NCT07485764 |
Metformin Combined With Secukinumab for Moderate-to-Severe Plaque Psoriasis in Overweight or Obese Chinese Patients |
NOT_YET_RECRUITING | PHASE4 |
| NCT07474792 |
Dose Ranging Study of ORKA-002 in Patients With Moderate-to-Severe Plaque Psoriasis |
RECRUITING | PHASE2 |
| NCT07449702 |
An Open-Label Extension Study of ORKA-001 in Participants With Plaque Psoriasis |
RECRUITING | PHASE2 |
| NCT07428941 |
Evaluating an Artificial Intelligence Tool to Help Primary Care Doctors Diagnose Skin Conditions. |
COMPLETED | |
| NCT07428915 |
Evaluating Legit.Health Plus Support for Improving Diagnosis of Generalized Pustular Psoriasis and Other Skin Conditions Among Primary Care Physicians and Dermatologists |
COMPLETED | |
| NCT07373847 |
Vunakizumab Combined With Recaticimab in Subjects With Moderate to Severe Plaque Psoriasis and Dyslipidemia |
NOT_YET_RECRUITING | PHASE4 |
| NCT07357831 |
A Phase III Trial To Evaluate The Efficacy And Safety Of MC2-01 Cream Compared To CAL/BDP Gel and Vehicle In Plaque Psoriasis Subjects |
RECRUITING | PHASE3 |
| NCT07326813 |
A Clinical Study to Evaluate the Efficacy and Safety of D-2570 in the Treatment of Moderate to Severe Plaque Psoriasis |
RECRUITING | PHASE3 |
